Family practice patients' use of acetylsalicylic acid for cardiovascular disease prevention

被引:0
|
作者
Kolber, Michael [1 ]
Sharif, Nadder [2 ]
Marceau, Raelene
Szafran, Olga [1 ]
机构
[1] Univ Alberta, Dept Family Med, Edmonton, AB T6G 2C8, Canada
[2] Univ Western Ontario, Div Emergency Med, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada
关键词
LOW-DOSE ASPIRIN; MYOCARDIAL-INFARCTION; RISK; EVENTS; HYPERTENSION; PERCEPTIONS; OUTCOMES; ADULTS;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To determine the prevalence of acetylsalicylic acid (ASA) use among family practice patients and the proportions of patients using ASA for primary and secondary cardiovascular prevention. Design Cross-sectional, self-reported, waiting room questionnaire. Setting Two family medicine clinics in Alberta. Participants Patients 50 years of age and older. Main outcome measures Overall prevalence of ASA use, proportion of ASA use for primary or secondary cardiovascular prevention, ASA use by patient age and sex, the proportion of patients who initiated ASA therapy on the advice of a physician, adverse events, and patient beliefs about ASA therapy. Results A total of 807 patients completed the questionnaire; the response rate was 89.1%. Overall, 39.8% of patients reported taking ASA regularly. Of those who took ASA, 87.0% did so for cardiovascular prevention (53.1% for primary prevention and 46.9% for secondary prevention). Of patients taking ASA for primary prevention, 62.8% did so upon the advice of their family physicians. Patients who took ASA believed that the benefits of taking ASA outweighed the risks; those who did not take ASA were unsure of the benefit-to-risk profile. Conclusion Many family practice patients take ASA, and more than half of those taking ASA take it for primary cardiovascular prevention. Family physicians appear to have an influence on patients' decisions to take ASA. Educating family physicians and patients about the potential benefits and risks of ASA therapy would help promote the use of ASA in those who might receive the greatest overall benefit.
引用
收藏
页码:55 / 61
页数:7
相关论文
共 50 条
  • [21] Acetylsalicylic acid in the primary and secondary prevention of vascular disease
    Schroer, K.
    Nitschmann, S.
    INTERNIST, 2010, 51 (10): : 1330 - +
  • [22] Represcription of Low-Dose Acetylsalicylic Acid After Discontinuation in Patients Receiving Treatment for Secondary Cardiovascular Disease Prevention in the UK
    Martin-Merino, Elisa
    Johansson, Saga
    Nagy, Peter
    Garcia Rodriguez, Luis A.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (04) : 319 - 326
  • [23] Represcription of Low-Dose Acetylsalicylic Acid After Discontinuation in Patients Receiving Treatment for Secondary Cardiovascular Disease Prevention in the UK
    Elisa Martín-Merino
    Saga Johansson
    Péter Nagy
    Luis A. García Rodríguez
    American Journal of Cardiovascular Drugs, 2014, 14 : 319 - 326
  • [24] Cardiovascular and gastrointestinal consequences of discontinuation with low-dose acetylsalicylic acid therapy in patients with cardiovascular disease
    Garcia Rodriguez, L. A.
    Cea Soriano, L.
    Bueno, H.
    Lanas, A.
    Johansson, S.
    EUROPEAN HEART JOURNAL, 2012, 33 : 495 - 495
  • [25] Cardiovascular prevention: from the guidelines to the family practice
    Bleckwenn M.
    Weckbecker K.
    MMW - Fortschritte der Medizin, 2018, 160 (13) : 54 - 61
  • [26] Efficacy and safety of acetylsalicylic acid in primary and secondary prevention of cardiovascular diseases
    Tolpygina, S. N.
    Martsevich, S. Yu.
    Khoseva, E. N.
    Kiseleva, N. V.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2012, 8 (02) : 205 - 210
  • [27] Cardiovascular Disease Prevention in a Gynecology Practice
    Bianco, Colleen E.
    JOURNAL OF CARDIOVASCULAR NURSING, 2014, 29 (05) : 400 - 400
  • [28] Acetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?
    Sirois, Caroline
    Couture, Julie
    GrEgoire, Jean-Pierre
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2012, 3 (05) : 213 - 226
  • [29] Incidence and predictors of haemorrhagic stroke in a cohort of patients receiving acetylsalicylic acid for secondary prevention of cardiovascular events
    Gonzalez-Perez, A.
    Saez, M. E.
    Johansson, S.
    Himmelmann, A.
    Garcia Rodriguez, L. A.
    EUROPEAN HEART JOURNAL, 2014, 35 : 25 - 25
  • [30] Folic Acid Supplementation for Stroke Prevention in Patients With Cardiovascular Disease
    Tian, Tao
    Yang, Kun-Qi
    Cui, Jin-Gang
    Zhou, Lan-Lan
    Zhou, Xian-Liang
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 354 (04): : 379 - 387